Refractory, primary Central Nervous System Neoplasm Active Not Recruiting Phase 1 Trials for Irinotecan (DB00762)

Also known as: Refractory Primary Central Nervous System Neoplasm

DBCOND0142769 (Refractory, primary Central Nervous System Neoplasm)Active Not Recruiting1 IdentifierTitlePurposeDrugs
NCT02975882Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid TumorsTreatment
NCT03323034Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or LymphomaTreatment